Research advances in esophageal diseases: Bench to bedside

F1000Prime Reports

Volumn 5, Issue , 2013, Pages

  Di Pietro, Massimiliano ^a   Fitzgerald, Rebecca C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; BACLOFEN; BOTULINUM TOXIN A; CITALOPRAM; EOTAXIN 3; ESOMEPRAZOLE; FLUTICASONE; INTERLEUKIN 13; INTERLEUKIN 5; MAJOR BASIC PROTEIN; NOTCH RECEPTOR; PROTEIN P53; PROTON PUMP INHIBITOR; TOLL LIKE RECEPTOR 4; TRANSCRIPTION FACTOR SOX9; TRANSFORMING GROWTH FACTOR BETA; ZINC TRANSPORTER;

ALLERGIC REACTION; ARTICLE; BARRETT ESOPHAGUS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CHROMOENDOSCOPY; CLINICAL RESEARCH; CONFOCAL LASER MICROSCOPY; CONFOCAL MICROSCOPY; DYSPEPSIA; DYSPHAGIA; EARLY DIAGNOSIS; ENDOSCOPIC THERAPY; ENVIRONMENTAL FACTOR; EOSINOPHILIC ESOPHAGITIS; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL PH MONITORING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS ACHALASIA; ESOPHAGUS CANCER; ESOPHAGUS CANDIDIASIS; ESOPHAGUS DISEASE; ESOPHAGUS DYSPLASIA; ESOPHAGUS FUNCTION DISORDER; ESOPHAGUS SPASM; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL MOTILITY DISORDER; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC SUSCEPTIBILITY; HIATUS HERNIA; HIGH AMPLITUDE PERISTALTIC ESOPHAGEAL CONTRACTION; HUMAN; HYPERTENSIVE LOWER ESOPHAGEAL SPHINCTER; IMMUNOHISTOCHEMISTRY; IRRITABLE COLON; LIFESTYLE; META ANALYSIS (TOPIC); NON EROSIVE REFLUX DISEASE; NONHUMAN; OUTPATIENT DEPARTMENT; PATHOGENESIS; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; TREATMENT RESPONSE;

EID: 84885654397     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P5-44     Document Type: Article

References (96)

1. Kennedy T, Jones R: The prevalence of gastro-oesophageal reflux symptoms in a UK population and the consultation behaviour of patients with these symptoms. Aliment Pharmacol Ther 2000, 14:1589-94. (Pubitemid 32011732)
2. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ: Prevalence and clinical spectrum of gastroesophageal reflux: a populationbased study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448-56. (Pubitemid 27181367)
3. Peery AF, Dellon ES, Lund J, Crockett SD, McGowan CE, Bulsiewicz WJ, Gangarosa LM, Thiny MT, Stizenberg K, Morgan DR, Ringel Y, Kim HP, Dibonaventura MD, Carroll CF, Allen JK, Cook SF, Sandler RS, Kappelman MD, Shaheen NJ: Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012, 143:1179-87.e1-3.
4. Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R: Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537-45. (Pubitemid 36384812)
5. Chu C, Zhen Y, Lv G, Li C, Li Z, Qi Q, Gu X, Yu T, Zhang T, Zhou C, Rui-Ji, Li Y: Microalterations of esophagus in patients with nonerosive reflux disease: in-vivo diagnosis by confocal laser endomicroscopy and its relationship with gastroesophageal reflux. Am J Gastroenterol 2012, 107:864-74.
6. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME: Shortterm treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013, 5:CD002095.
7. Zerbib F, Belhocine K, Simon M, Capdepont M, Mion F, Des Bruley Varannes S, Galmiche J: Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut 2012, 61:501-6.
8. Kahrilas PJ, Jonsson A, Denison H, Wernersson B, Hughes N, Howden CW: Concomitant symptoms itemized in the Reflux Disease Questionnaire are associated with attenuated heartburn response to acid suppression. Am J Gastroenterol 2012, 107:1354-60.
9. Altan E, Blondeau K, Pauwels A, Farré R, Tack J: Evolving pharmacological approaches in gastroesophageal reflux disease. Expert Opin Emerg Drugs 2012, 17:347-59.
10. Rohof WO, Bennink RJ, Ruigh AA de, Hirsch DP, Zwinderman AH, Boeckxstaens GE: Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012, 61:1670-7.
11. Orr WC, Goodrich S, Wright S, Shepherd K, Mellow M: The effect of baclofen on nocturnal gastroesophageal reflux and measures of sleep quality: a randomized, cross-over trial. Neurogastroenterol Motil 2012, 24:553-9, e253.
12. Viazis N, Keyoglou A, Kanellopoulos AK, Karamanolis G, Vlachogiannakos J, Triantafyllou K, Ladas SD, Karamanolis DG: Selective serotonin reuptake inhibitors for the treatment of hypersensitive esophagus: a randomized, double-blind, placebocontrolled study. Am J Gastroenterol 2012, 107:1662-7.
13. Galmiche J, Hatlebakk J, Attwood S, Ell C, Fiocca R, Eklund S, Långström G, Lind T, Lundell L: Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011, 305:1969-77.
14. Broeders JA, Roks DJ, Ahmed Ali U, Watson DI, Baigrie RJ, Cao Z, Hartmann J, Maddern GJ: Laparoscopic anterior 180-degree versus nissen fundoplication for gastroesophageal reflux disease: systematic review and meta-analysis of randomized clinical trials. Ann Surg 2013, 257:850-9.
15. Lagergren J, Bergström R, Lindgren A, Nyrén O: Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999, 340:825-31. (Pubitemid 29142625)
16. Taylor JB, Rubenstein JH: Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol 2010, 105:1729, 1730-7; quiz 1738.
17. Di Pietro M, Fitzgerald RC: Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet 2009, 126:233-46.
18. Souza RF, Krishnan K, Spechler SJ: Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 2008, 295:G211-8.
19. Ryan AM, Duong M, Healy L, Ryan SA, Parekh N, Reynolds JV, Power DG: Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol 2011, 35:309-19.
20. Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, Corcoran-Schwartz IM, Wilburn DL, Montgomery EA, Wang JS, Jenkins NA, Copeland NA, Harmon JW, Phillips WA, Watkins DN: Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 2010, 138:1810-22.
21. Gibson MK, Zaidi AH, Davison JM, Sanz AF, Hough B, Komatsu Y, Kosovec JE, Bhatt A, Malhotra U, Foxwell T, Rotoloni CL, Hoppo T, Jobe BA: Prevention of Barrett esophagus and esophageal adenocarcinoma by smoothened inhibitor in a rat model of gastroesophageal reflux disease. Ann Surg 2013, 258:82-8.
22. Song S, Maru DM, Ajani JA, Chan C, Honjo S, Lin H, Correa A, Hofstetter WL, Davila M, Stroehlein J, Mishra L: Loss of TGF-β adaptor β2SP activates notch signaling and SOX9 expression in esophageal adenocarcinoma. Cancer Res 2013, 73:2159-69.
23. The cancer genome atlas - National Cancer Institute [https://tcgadata. nci.nih.gov/tcga/tcgaCancerDetails.jsp?diseaseType=ESCA&disease Name=Esophagealcarcinoma]
24. International Cancer Genome Consortium [http://icgc.org/icgc/cgp/72/508/ 70708]
25. Dulak AM, Stojanov P, Peng S, Lawrence MS, Fox C, Stewart C, Bandla S, Imamura Y, Schumacher SE, Shefler E, McKenna A, Carter SL, Cibulskis K, Sivachenko A, Saksena G, Voet D, Ramos AH, Auclair D, Thompson K, Sougnez C, Onofrio RC, Guiducci C, Beroukhim R, Zhou Z, Lin L, Lin J, Reddy R, Chang A, Landrenau R, Pennathur A, et al.: Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013, 45:478-86.
26. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE, Elston R, Eng C: Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006, 15:1668-73. (Pubitemid 44497103)
27. Su Z, Gay LJ, Strange A, Palles C, Band G, Whiteman DC, Lescai F, Langford C, Nanji M, Edkins S, van der Winkel A, Levine D, Sasieni P, Bellenguez C, Howarth K, Freeman C, Trudgill N, Tucker AT, Pirinen M, Peppelenbosch MP, van der Laan LJW, Kuipers EJ, Drenth JPH, Peters WH, Reynolds JV, Kelleher DP, McManus R, Grabsch H, Prenen H, Bisschops R, et al.: Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet 2012, 44:1131-6.
28. Dura P, van Veen EM, Salomon J, te Morsche RHM, Roelofs HMJ, Kristinsson JO, Wobbes T, Witteman BJM, Tan ACITL, Drenth JPH, Peters WHM: Barrett associated MHC and FOXF1 variants also increase esophageal carcinoma risk. Int J Cancer 2013, 133:1751-5.
29. Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, Murray LJ: Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011, 103:1049-57.
30. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S, Howden CW: The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012, 61:970-6.
31. Hvid-Jensen F, Pedersen L, Drewes AM, Sørensen HT, Funch-Jensen P: Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 2011, 365:1375-83.
32. Corley DA, Mehtani K, Quesenberry C, Zhao W, Boer J de, Weiss NS: Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 2013, 145:312-9.e1.
33. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, O'Donovan M, Novelli M, Lovat LB, Eng WS, Mahal LK, Brindle KM, Fitzgerald RC: Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nat Med 2012, 18:315-21.
34. Sturm MB, Joshi BP, Lu S, Piraka C, Khondee S, Elmunzer BJ, Kwon RS, Beer DG, Appelman HD, Turgeon DK, Wang TD: Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med 2013, 5:184ra61.
35. Thrift AP, Whiteman DC: The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann Oncol 2012, 23:3155-62.
36. Curvers WL, Kate FJ ten, Krishnadath KK, Visser M, Elzer B, Baak LC, Bohmer C, Mallant-Hent RC, van Oijen A, Naber AH, Scholten P, Busch OR, Blaauwgeers HGT, Meijer GA, Bergman JJGHM: Lowgrade dysplasia in Barrett's esophagus: overdiagnosed and underestimated. Am J Gastroenterol 2010, 105:1523-30.
37. Wani S, Falk GW, Post J, Yerian L, Hall M, Wang A, Gupta N, Gaddam S, Singh M, Singh V, Chuang K, Boolchand V, Gavini H, Kuczynski J, Sud P, Bansal A, Rastogi A, Mathur SC, Young P, Cash B, Goldblum J, Lieberman DA, Sampliner RE, Sharma P: Risk factors for progression of low-grade dysplasia in patients with Barrett's esophagus. Gastroenterology 2011, 141:1179-86, 1186.e1.
38. Anaparthy R, Gaddam S, Kanakadandi V, Alsop BR, Gupta N, Higbee AD, Wani SB, Singh M, Rastogi A, Bansal A, Cash BD, Young PE, Lieberman DA, Falk GW, Vargo JJ, Thota P, Sampliner RE, Sharma P: Association Between Length of Barrett's Esophagus and Risk of High-grade Dysplasia or Adenocarcinoma in Patients Without Dysplasia. Clin Gastroenterol Hepatol 2013.
39. Fels Elliott DR, Fitzgerald RC: Molecular markers for Barrett's esophagus and its progression to cancer. Curr Opin Gastroenterol 2013, 29:437-45.
40. Kastelein F, Biermann K, Steyerberg EW, Verheij J, Kalisvaart M, Looijenga LHJ, Stoop HA, Walter L, Kuipers EJ, Spaander MCW, Bruno MJ: Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus. Gut 2012.
41. Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, Emery J, Boussioutas A, Morris H, Walter FM, Pharoah P, Hardwick RH, Fitzgerald RC: Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010, 341:c4372.
42. Benaglia T, Sharples LD, Fitzgerald RC, Lyratzopoulos G: Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology 2013, 144:62-73.e6.
43. Gora MJ, Sauk JS, Carruth RW, Gallagher KA, Suter MJ, Nishioka NS, Kava LE, Rosenberg M, Bouma BE, Tearney GJ: Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat Med 2013, 19:238-40.
44. Shaheen NJ, Overholt BF, Sampliner RE, Wolfsen HC, Wang KK, Fleischer DE, Sharma VK, Eisen GM, Fennerty MB, Hunter JG, Bronner MP, Goldblum JR, Bennett AE, Mashimo H, Rothstein RI, Gordon SR, Edmundowicz SA, Madanick RD, Peery AF, Muthusamy VR, Chang KJ, Kimmey MB, Spechler SJ, Siddiqui AA, Souza RF, Infantolino A, Dumot JA, Falk GW, Galanko JA, Jobe BA, et al.: Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology 2011, 141:460-8.
45. Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Hölscher AH: Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg 2011, 254:67-72.
46. Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S, Miah H, Smart HL, Bhandari P, Smith LA, Willert R, Fullarton G, Morris J, Di Pietro M, Gordon C, Penman I, Barr H, Patel P, Boger P, Kapoor N, Mahon B, Hoare J, Narayanasamy R, O'Toole D, Cheong E, Direkze NC, Ang Y, Novelli M, Banks MR, Lovat LB: Radiofrequency ablation and endoscopic mucosal resection for dysplastic barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013, 145:87-95.
47. Pouw RE, Wirths K, Eisendrath P, Sondermeijer CM, Kate FJ ten, Fockens P, Devière J, Neuhaus H, Bergman JJ: Efficacy of radiofrequency ablation combined with endoscopic resection for barrett's esophagus with early neoplasia. Clin Gastroenterol Hepatol 2010, 8:23-9.
48. Phoa KN, Pouw RE, van Vilsteren FGI, Sondermeijer CMT, Kate FJW ten, Visser M, Meijer SL, van Berge Henegouwen MI, Weusten BLAM, Schoon EJ, Mallant-Hent RC, Bergman JJGHM: Remission of Barrett's esophagus with early neoplasia 5 years after radiofrequency ablation with endoscopic resection: a Netherlands cohort study. Gastroenterology 2013, 145:96-104.
49. Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, Sanders S, Gay L, Pech O, Longcroft-Wheaton G, Romero Y, Inadomi J, Tack J, Corley DA, Manner H, Green S, Al Dulaimi D, Ali H, Allum B, Anderson M, Curtis H, Falk G, Fennerty MB, Fullarton G, Krishnadath K, Meltzer SJ, Armstrong D, Ganz R, Cengia G, Going JJ, et al.: Consensus statements for management of Barrett's dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology 2012, 143:336-46.
50. Ong CJ, Shapiro J, Nason KS, Davison JM, Liu X, Ross-Innes C, O'Donovan M, Dinjens WNM, Biermann K, Shannon N, Worster S, Schulz LKE, Luketich JD, Wijnhoven BPL, Hardwick RH, Fitzgerald RC: Three-gene immunohistochemical panel adds to clinical staging algorithms to predict prognosis for patients with esophageal adenocarcinoma. J Clin Oncol 2013, 31:1576-82.
51. Bosetti C, Levi F, Ferlay J, Garavello W, Lucchini F, Bertuccio P, Negri E, La Vecchia C: Trends in oesophageal cancer incidence and mortality in Europe. Int J Cancer 2008, 122:1118-29. (Pubitemid 351214012)
52. Wu C, Kraft P, Zhai K, Chang J, Wang Z, Li Y, Hu Z, He Z, Jia W, Abnet CC, Liang L, Hu N, Miao X, Zhou Y, Liu Z, Zhan Q, Liu Y, Qiao Y, Zhou Y, Jin G, Guo C, Lu C, Yang H, Fu J, Yu D, Freedman ND, Ding T, Tan W, Goldstein AM, Wu T, et al.: Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. Nat Genet 2012, 44:1090-7.
53. Wu C, Li D, Jia W, Hu Z, Zhou Y, Yu D, Tong T, Wang M, Lin D, Qiao Y, Zhou Y, Chang J, Zhai K, Wang M, Wei L, Tan W, Shen H, Zeng Y, Lin D: Genome-wide association study identifies common variants in SLC39A6 associated with length of survival in esophageal squamous-cell carcinoma. Nat Genet 2013, 45:632-8.
54. Zhang S,HuangQ, Yang H, Xie X, Luo K,Wen J, CaiX, Yang F, Hu Y, Fu J: Correlation of p53 status with the response to chemotherapybased treatment in esophageal cancer: a meta-analysis. Ann Surg Oncol 2013, 20:2419-27.
55. Ma S, Bao JYJ, Kwan PS, Chan YP, Tong CM, Fu L, Zhang N, Tong AHY, Qin Y, Tsao SW, Chan KW, Lok S, Guan X: Identification of PTK6, via RNA sequencing analysis, as a suppressor of esophageal squamous cell carcinoma. Gastroenterology 2012, 143:675-86.e1-12.
56. Song L, Gong H, Lin C, Wang C, Liu L, Wu J, Li M, Li J: Flotillin-1 promotes tumor necrosis factor-a receptor signaling and activation of NF-kB in esophageal squamous cell carcinoma cells. Gastroenterology 2012, 143:995-1005.e12.
57. Yamashina T, Ishihara R, Nagai K, Matsuura N, Matsui F, Ito T, Fujii M, Yamamoto S, Hanaoka N, Takeuchi Y, Higashino K, Uedo N, Iishi H: Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol 2013, 108:544-51.
58. Boller D, Spieler P, Schoenegg R, Neuweiler J, Kradolfer D, Studer R, Grossenbacher R, Zuercher U, Meyenberger C, Borovicka J: Lugol chromoendoscopy combined with brush cytology in patients at risk for esophageal squamous cell carcinoma. Surg Endosc 2009, 23:2748-54.
59. Wong GS, Habibollahi P, Heidari P, Lee J, Klein-Szanto AJ, Waldron TJ, Gimotty P, Nakagawa H, Taylor PR, Wang TC, Mahmood U, Rustgi AK: Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice. Gastroenterology 2013, 144:294-7.
60. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA: ACGclinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol 2013, 108:679-92; quiz 693.
61. Kim HP, Vance RB, Shaheen NJ, Dellon ES: The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin Gastroenterol Hepatol 2012, 10:988-96.e5.
62. Moawad FJ, Veerappan GR, Dias JA, Baker TP, Maydonovitch CL, Wong RKH: Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013, 108:366-72.
63. Alexander JA, Jung KW, Arora AS, Enders F, Katzka DA, Kephardt GM, Kita H, Kryzer LA, Romero Y, Smyrk TC, Talley NJ: Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012, 10:742-749.e1.
64. Dellon ES, Chen X, Miller CR, Woosley JT, Shaheen NJ: Diagnostic utility of major basic protein, eotaxin-3, and leukotriene enzyme staining in eosinophilic esophagitis. Am J Gastroenterol 2012, 107:1503-11.
65. Rothenberg ME: Biology and treatment of eosinophilic esophagitis. Gastroenterology 2009, 137:1238-49.
66. Gonsalves N, Yang G, Doerfler B, Ritz S, Ditto AM, Hirano I: Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012, 142:1451-9.e1; quiz e14-5.
67. Lucendo AJ, Arias Á, González-Cervera J, Yagüe-Compadre JL, Guagnozzi D, Angueira T, Jiménez-Contreras S, González-Castillo S, Rodríguez-Domíngez B, Rezende LC de, Tenias JM: Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 2013, 131:797-804.
68. Markowitz JE, Spergel JM, Ruchelli E, Liacouras CA: Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. Am J Gastroenterol 2003, 98:777-82. (Pubitemid 36576301)
69. Peterson KA, Byrne KR, Vinson LA, Ying J, Boynton KK, Fang JC, Gleich GJ, Adler DG, Clayton F: Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol 2013, 108:759-66.
70. Spergel JM, Rothenberg ME, Collins MH, Furuta GT, Markowitz JE, Fuchs G, O'Gorman MA, Abonia JP, Young J, Henkel T, Wilkins HJ, Liacouras CA: Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012, 129:456-63, 463.e1-3.
71. Otani IM, Anilkumar AA, Newbury RO, Bhagat M, Beppu LY, Dohil R, Broide DH, Aceves SS: Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. J Allergy Clin Immunol 2013, 131:1576-82.
72. Bredenoord AJ, Fox M, Kahrilas PJ, Pandolfino JE, Schwizer W, Smout AJPM: Chicago classification criteria of esophageal motility disorders defined in high resolution esophageal pressure topography. Neurogastroenterol Motil 2012, 24(Suppl 1): 57-65.
73. Carlson DA, Pandolfino JE: The Chicago criteria for esophageal motility disorders: what has changed in the past 5 years? Curr Opin Gastroenterol 2012, 28:395-402.
74. Tsutsui H, Manabe N, Uno M, Imamura H, Kamada T, Kusunoki H, Shiotani A, Hata J, Harada T, Haruma K: Esophageal motor dysfunction plays a key role in GERD with globus sensation-analysis of factors promoting resistance to PPI therapy. Scand J Gastroenterol 2012, 47:893-9.
75. Fisichella PM, Carter SR, Robles LY: Presentation, diagnosis, and treatment of oesophageal motility disorders. Dig Liver Dis 2012, 44:1-7.
76. Vanuytsel T, Bisschops R, Farré R, Pauwels A, Holvoet L, Arts J, Caenepeel P, Wulf D de, Mimidis K, Rommel N, Tack J: Botulinum toxin reduces Dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol 2013, 11:1115-1121.e2.
77. Elliott TR, Wu PI, Fuentealba S, Szczesniak M, Carle DJ de, Cook IJ: Long-term outcome following pneumatic dilatation as initial therapy for idiopathic achalasia: an 18-year single-centre experience. Aliment Pharmacol Ther 2013, 37:1210-9.
78. Weber CE, Davis CS, Kramer HJ, Gibbs JT, Robles L, Fisichella PM: Medium and long-term outcomes after pneumatic dilation or laparoscopic Heller myotomy for achalasia: a meta-analysis. Surg Laparosc Endosc Percutan Tech 2012, 22:289-96.
79. Verlaan T, Rohof WO, Bredenoord AJ, Eberl S, Rösch T, Fockens P: Effect of peroral endoscopic myotomy on esophagogastric junction physiology in patients with achalasia. Gastrointest Endosc 2013, 78:39-44.
80. Lee BH, Shim KY, Hong SJ, Bok GH, Cho J, Lee TH, Cho JY: Peroral endoscopic myotomy for treatment of achalasia: initial results of a korean study. Clin Endosc 2013, 46:161-7.
81. Sharata A, Kurian AA, Dunst CM, Bhayani NH, Reavis KM, Swanström LL: Peroral endoscopic myotomy (POEM) is safe and effective in the setting of prior endoscopic intervention. J Gastrointest Surg 2013, 17:1188-92.
82. Renteln D von, Fuchs K, Fockens P, Bauerfeind P, Vassiliou MC, Werner YB, Fried G, Breithaupt W, Heinrich H, Bredenoord AJ, Kersten JF, Verlaan T, Trevisonno M, Rösch T: Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. Gastroenterology 2013, 145:309-11.e1-3.
83. Hungness ES, Teitelbaum EN, Santos BF, Arafat FO, Pandolfino JE, Kahrilas PJ, Soper NJ: Comparison of perioperative outcomes between peroral esophageal myotomy (POEM) and laparoscopic Heller myotomy. J Gastrointest Surg 2013, 17:228-35.
84. Perry KA, Banerjee A, Melvin WS: Radiofrequency energy delivery to the lower esophageal sphincter reduces esophageal acid exposure and improves GERD symptoms: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 2012, 22:283-8.
85. Rodríguez L, Rodriguez P, Gómez B, Ayala JC, Saba J, Perez-Castilla A, Galvao Neto M, Crowell MD: Electrical stimulation therapy of the lower esophageal sphincter is successful in treating GERD: final results of open-label prospective trial. Surg Endosc 2013, 27:1083-92.
86. Ganz RA, Peters JH, Horgan S: Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 2013, 368:2039-40.
87. Testoni PA, Vailati C, Testoni S, Corsetti M: Transoral incisionless fundoplication (TIF 2.0) with EsophyX for gastroesophageal reflux disease: long-term results and findings affecting outcome. Surg Endosc 2012, 26:1425-35.
88. Rubenstein JH, Morgenstern H, Chey WD, Murray J, Scheiman JM, Schoenfeld P, Appelman HD, McMahon L, Metko V, Kellenberg J, Kalish T, Baker J, Inadomi JM: Protective role of gluteofemoral obesity in erosive oesophagitis and Barrett's oesophagus. Gut 2013.
89. Balasubramanian G, Singh M, Gupta N, Gaddam S, Giacchino M, Wani SB, Moloney B, Higbee AD, Rastogi A, Bansal A, Sharma P: Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am J Gastroenterol 2012, 107:1655-61.
90. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF, Metko V, Near E, Kellenberg J, Kalish T, Inadomi JM: Prediction of Barrett's esophagus among men. Am J Gastroenterol 2013, 108:353-62.
91. Rajendra S, Wang B, Snow ET, Sharma P, Pavey D, Merrett N, Ball MJ, Brain T, Fernando R, Robertson IK: Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma. Am J Gastroenterol 2013, 108:1082-93.
92. Guo F, Liu Y, Wang X, He Z, Weiss NS, Madeleine MM, Liu F, Tian X, Song Y, Pan Y, Ning T, Yang H, Shi X, Lu C, Cai H, Ke Y: Human papillomavirus infection and esophageal squamous cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev 2012, 21:780-5.
93. Steevens J, Schouten LJ, Goldbohm RA, van den Brandt PA: Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer: a prospective cohort study. Gut 2010, 59:39-48.
94. Bagnardi V, Rota M, Botteri E, Tramacere I, Islami F, Fedirko V, Scotti L, Jenab M, Turati F, Pasquali E, Pelucchi C, Bellocco R, Negri E, Corrao G, Rehm J, Boffetta P, La Vecchia C: Light alcohol drinking and cancer: a meta-analysis. Ann Oncol 2013, 24:301-8.
95. Keszei AP, Schouten LJ, Goldbohm RA, van den Brandt PA: Red and processed meat consumption and the risk of esophageal and gastric cancer subtypes in The Netherlands Cohort Study. Ann Oncol 2012, 23:2319-26.
96. Jeurnink SM, Büchner FL, Bueno-de-Mesquita HB, Siersema PD, Boshuizen HC, Numans ME, Dahm CC, Overvad K, Tjønneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Kaaks R, Teucher B, Boeing H, Buijsse B, Trichopoulou A, Benetou V, Zylis D, Palli D, Sieri S, Vineis P, Tumino R, Panico S, Ocké MC, Peeters PHM, Skeie G, Brustad M, Lund E, et al.: Variety in vegetable and fruit consumption and the risk of gastric and esophageal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 2012, 131:E963-73.